Infection Rates Stable with Rituximab (CME/CE)
(MedPage Today) -- No increase with additional courses of treatment (Source: MedPage Today Infectious Disease)
Source: MedPage Today Infectious Disease - October 19, 2018 Category: Infectious Diseases Source Type: news

FDA approves label update for Roche ’s Mabthera/Rituxan (rituximab) in two rare forms of vasculitis
Roche announced today that the U.S. Food and Drug Administration (FDA) has approved an update to the MabThera/Rituxan ® (rituximab) label to include information on follow up treatment of adult patients with Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) who have achieved disease control with induction treatment. (Source: Roche Investor Update)
Source: Roche Investor Update - October 19, 2018 Category: Pharmaceuticals Source Type: news

No Chemo; Rituximab Alone for Indolent Lymphoma? No Chemo; Rituximab Alone for Indolent Lymphoma?
New results showing a 10-year overall survival rate of 73% with rituximab alone suggest that patients can skip chemotherapy. But this may not be appropriate for all patients, suggests an expert.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 18, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Updated GADOLIN Study Shows Survival Benefit in Indolent NHL Updated GADOLIN Study Shows Survival Benefit in Indolent NHL
An updated analysis of the GADOLIN study confirms the PFS benefit of obinutuzumab and bendamustine in rituximab-refractory indolent non-Hodgkin lymphoma.Journal of Clinical Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 12, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

U.S. FDA Panel Backs Celltrion Copycat of Roche Blood Cancer Drug U.S. FDA Panel Backs Celltrion Copycat of Roche Blood Cancer Drug
Celltrion Inc's biosimilar of Roche Holding AG's blockbuster cancer drug, Rituxan (rituximab), on Wednesday won unanimous backing from an advisory panel to the U.S. Food and Drug Administration.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 11, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

FDA Committee Backs Rituximab Biosimilar for Lymphoma
(MedPage Today) -- Unanimous approval recommendation for CT-P10 in NHL (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - October 10, 2018 Category: Hematology Source Type: news

U.S. FDA panel backs Celltrion copycat of Roche blood cancer drug
Celltrion Pharm Inc's biosimilar of Roche Holding AG's blockbuster cancer drug, Rituxan, on Wednesday won unanimous backing from an advisory panel to the U.S. Food and Drug Administration. (Source: Reuters: Health)
Source: Reuters: Health - October 10, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Rituximab Over Tacrolimus in Steroid-Dependent Nephrotic Syndrome? Rituximab Over Tacrolimus in Steroid-Dependent Nephrotic Syndrome?
Dr Desai reviews recent trials comparing steroid-sparing agents used to treat corticosteroid-dependent children with nephrotic syndrome.Medscape Nephrology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 8, 2018 Category: Consumer Health News Tags: Nephrology Viewpoint Source Type: news

Rituximab and the Risk of Serious Infections in RA Patients Rituximab and the Risk of Serious Infections in RA Patients
The question of whether treatment with rituximab is associated with an increased risk of serious infections is controversial. This editorial explores the issue.Rheumatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 24, 2018 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

Roche announces CHMP recommendation for EU approval of Venclyxto plus MabThera for people with previously treated chronic lymphocytic leukaemia
Roche announced today that the EU Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Venclyxto ® (venetoclax) in combination with MabThera® (rituximab) for the treatment of people with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy. (Source: Roche Investor Update)
Source: Roche Investor Update - September 21, 2018 Category: Pharmaceuticals Source Type: news

Antiretroviral Therapy, Rituximab Active in Aids-Related DLBCL
Antiretroviral therapy and rituximab show promise in aids-related diffuse large B-cell lymphoma patients. (Source: CancerNetwork)
Source: CancerNetwork - September 13, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

Rituximab & #43; Lenalidomide Effective in Follicular Lymphoma
TUESDAY, Sept. 11, 2018 -- Rituximab plus lenalidomide has similar efficacy to rituximab plus chemotherapy among patients with previously untreated follicular lymphoma, according to a study published in the Sept. 6 issue of the New England Journal... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 11, 2018 Category: Pharmaceuticals Source Type: news

FDA approves J & amp;J's non-chemotherapy combination regimen for rare blood cancer
Approval expands the label for Imbruvica in WM to include combination use with rituximab (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - August 28, 2018 Category: Pharmaceuticals Source Type: news

U.S. FDA Approves IMBRUVICA ® (ibrutinib) Plus Rituximab as First Non-Chemotherapy Combination Regimen for Patients with Waldenström’s Macroglobulinemia, a Rare Blood Cancer
(Source: Johnson and Johnson)
Source: Johnson and Johnson - August 27, 2018 Category: Pharmaceuticals Source Type: news

FDA Approves Imbruvica (ibrutinib) Plus Rituximab for Patients with Waldenstr öm’s Macroglobulinemia
HORSHAM, Pa., August 27, 2018 – The Janssen Pharmaceutical Companies of Johnson& Johnson today announced the U.S. Food and Drug Administration (FDA) approval of Imbruvica (ibrutinib) in combination with rituximab for the treatment of... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 27, 2018 Category: Drugs & Pharmacology Source Type: news

Rituximab in Takayasu Arteritis: An Unmet Hope Rituximab in Takayasu Arteritis: An Unmet Hope
Is there sufficient evidence to support the use of rituximab therapy for Takayasu arteritis? This editorial explores the issue.Rheumatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 31, 2018 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

CD19 Antibody MOR208 in Relapsed or Refractory B-Cell NHL CD19 Antibody MOR208 in Relapsed or Refractory B-Cell NHL
MOR208, an Fc-engineered, humanized, CD19 antibody, shows promise in rituximab-refractory B-cell NHL and follicular lymphoma.Annals of Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 26, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Lower Risk Of Follicular Lymphoma Transformation With Rituximab Lower Risk Of Follicular Lymphoma Transformation With Rituximab
The risk of transformation of follicular lymphoma is significantly lower with rituximab treatment, according to results from the Aristotle study.Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - July 18, 2018 Category: Pathology Tags: Hematology-Oncology News Source Type: news

Survival Boost With Maintenance Rituxumab in Follicular Lymphoma
In addition to significant improvements in 5-year OS and PFS with maintenance rituximab, there was a trend toward an association between maintenance and reduced transformation risk. (Source: CancerNetwork)
Source: CancerNetwork - July 18, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

rituximab (Rituxan)
Title: rituximab (Rituxan)Category: MedicationsCreated: 1/7/2001 12:00:00 AMLast Editorial Review: 7/12/2018 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - July 12, 2018 Category: Cancer & Oncology Source Type: news

Watch for Infections in Rituximab-Treated Vasculitis
(MedPage Today) -- Prophylaxis with trimethoprim-sulfamethoxazole lowered the risk by half (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - June 29, 2018 Category: Primary Care Source Type: news

Prolonged PFS With Obinutuzumab in Advanced FL, Regardless of Chemo Backbone
AEs were more common in patients assigned to obinutuzumab compared with rituximab; however, baseline characteristics differed between treatment arms. (Source: CancerNetwork)
Source: CancerNetwork - June 26, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

Lenalidomide/Rituximab Combo Effective in Advanced FL
Efficacy of lenalidomide plus rituximab was similar to chemotherapy induction in previously untreated symptomatic FL, with a better safety profile. (Source: CancerNetwork)
Source: CancerNetwork - June 26, 2018 Category: Cancer & Oncology Authors: John Schieszer Source Type: news

IMBRUVICA(R) (ibrutinib) Supplemental New Drug Application Accepted for Review by U.S. FDA with Potential to Broaden Treatment Use as a Combination Treatment Option with Rituximab in Waldenström's Macroglobulinemia (WM), A Rare Form of Blood Cancer
The filing is based on data from the Phase 3 iNNOVATE study, which suggest that IMBRUVICA plus rituximab may improve outcomes across all lines of Waldenström's macroglobulinemia (WM) treatment, including patients with prior lines of therapy and variou... Biopharmaceuticals, Oncology, FDA AbbVie, IMBRUVICA, ibrutinib, Waldenström's Macroglobulinemia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 25, 2018 Category: Pharmaceuticals Source Type: news

Novel Nonchemo Combo (Len-R) Effective in Follicular Lymphoma Novel Nonchemo Combo (Len-R) Effective in Follicular Lymphoma
A novel chemotherapy-free regimen containing lenalidomide and rituximab showed similar efficacy but less toxicity than the standard combination of rituximab and chemotherapy in the RELEVANCE trial.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 20, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Survival Longer With Obinutuzumab Compared to Rituximab in CLL Survival Longer With Obinutuzumab Compared to Rituximab in CLL
New longer-term results with overall survival data confirm the superiority of the newer agent over the earlier-generation anti-CD20 drug rituximab for previously untreated chronic lymphocytic leukemia (CLL).Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 20, 2018 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Venetoclax/Rituximab Combo Approved for CLL/SLL
FDA warns, however, about the possibility of TLS due to rapid tumor cell destruction. (Source: CancerNetwork)
Source: CancerNetwork - June 19, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

In DLBCL, Polatuzumab Combo Yields ‘Marked Improvement’ in CR, PFS, OS
Polatuzumab vedotin administered with bendamustine and rituximab significantly improved PET-based CR rates, PFS, and OS in DLBCL but not FL. (Source: CancerNetwork)
Source: CancerNetwork - June 15, 2018 Category: Cancer & Oncology Authors: John Schieszer Source Type: news

Rituximab Therapy in Lupus
No abstract available (Source: Lippincott's Bone and Joint Newsletter)
Source: Lippincott's Bone and Joint Newsletter - June 15, 2018 Category: Orthopaedics Tags: Perspective Source Type: news

AbbVie Announces New Undetectable Minimal Residual Disease Data from Phase 3 Relapsed/Refractory Chronic Lymphocytic Leukemia MURANO Trial of Venetoclax in Combination with Rituximab at 23rd European Hematology Association Annual Congress
83 percent (n=100) of 121 patients who achieved undetectable minimal residual disease (uMRD) at the end of combination therapy with VenR (n=194), maintained uMRD and were progression-free at 13.8 months of follow-up[1] uMRD response rates were consisten... Biopharmaceuticals, Oncology AbbVie, MURANO trial, venetoclax, chronic lymphocytic leukemia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 15, 2018 Category: Pharmaceuticals Source Type: news

New long-term data confirm Roche ’s Gazyva/Gazyvaro extends the lives of people with chronic lymphocytic leukaemia compared to MabThera/Rituxan
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced data from the final analysis of the CLL11 study evaluating Gazyva®/Gazyvaro® (obinutuzumab)-based treatment in previously untreated chronic lymphocytic leukaemia (CLL) which will be presented during the Presidential Symposium at the 23rd European Hematology Association (EHA) Annual Congress, 14 - 17 June, in Stockholm. (Source: World Pharma News)
Source: World Pharma News - June 15, 2018 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news

New long-term data confirm Roche ’s Gazyva/Gazyvaro extends the lives of people with chronic lymphocytic leukaemia compared to MabThera/Rituxan
Roche today announced data from the final analysis of the CLL11 study evaluating Gazyva ®/Gazyvaro® (obinutuzumab)-based treatment in previously untreated chronic lymphocytic leukaemia (CLL) which will be presented during the Presidential Symposium at the 23rd European Hematology Association (EHA) Annual Congress, 14 - 17 June, in Stockholm. (Source: Roche Media News)
Source: Roche Media News - June 15, 2018 Category: Pharmaceuticals Source Type: news

New long-term data confirm Roche ’s Gazyva/Gazyvaro extends the lives of people with chronic lymphocytic leukaemia compared to MabThera/Rituxan
Roche today announced data from the final analysis of the CLL11 study evaluating Gazyva ®/Gazyvaro® (obinutuzumab)-based treatment in previously untreated chronic lymphocytic leukaemia (CLL) which will be presented during the Presidential Symposium at the 23rd European Hematology Association (EHA) Annual Congress, 14 - 17 June, in Stockholm. (Source: Roche Investor Update)
Source: Roche Investor Update - June 15, 2018 Category: Pharmaceuticals Source Type: news

Roche announces FDA approval for Venclexta plus Rituxan for people with previously treated chronic lymphocytic leukaemia
Roche, announced today that the United States Food and Drug Administration (FDA) has approved Venclexta ® (venetoclax) in combination with Rituxan® (rituximab) for the treatment of people with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy. (Source: Roche Media News)
Source: Roche Media News - June 11, 2018 Category: Pharmaceuticals Source Type: news

Roche announces FDA approval for Venclexta plus Rituxan for people with previously treated chronic lymphocytic leukaemia
Roche, announced today that the United States Food and Drug Administration (FDA) has approved Venclexta ® (venetoclax) in combination with Rituxan® (rituximab) for the treatment of people with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy. (Source: Roche Investor Update)
Source: Roche Investor Update - June 11, 2018 Category: Pharmaceuticals Source Type: news

FDA approves Roche ’s MabThera/Rituxan (rituximab) for pemphigus vulgaris
Roche announced today that the US Food and Drug Administration (FDA) has approved MabThera/Rituxan ® (rituximab) for the treatment of adults with moderate to severe pemphigus vulgaris (PV), a rare, serious, potentially life-threatening condition characterised by progressive painful blistering of the skin and mucous membranes. (Source: Roche Investor Update)
Source: Roche Investor Update - June 8, 2018 Category: Pharmaceuticals Source Type: news

Deadly Skin Disorder Gets First New Drug in 60 Years
(MedPage Today) -- FDA approves rituximab (Rituxan) for pemphigus vulgaris (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - June 8, 2018 Category: Dermatology Source Type: news

Genentech Announces FDA Approval for Venclexta Plus Rituxan for People With Previously Treated Chronic Lymphocytic Leukemia
South San Francisco, CA -- June 8, 2018 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Venclexta (venetoclax) in combination with Rituxan ... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - June 8, 2018 Category: Drugs & Pharmacology Source Type: news

FDA Approves Genentech ’s Rituxan (rituximab) for Pemphigus Vulgaris
South San Francisco, CA -- June 7, 2018 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Rituxan (rituximab) for the treatment of adults with... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - June 7, 2018 Category: Drugs & Pharmacology Source Type: news

Combo Improves Outcomes in Waldenstrom's Macroglobulinema Combo Improves Outcomes in Waldenstrom's Macroglobulinema
The combination of ibrutinib plus rituximab dramatically extends progression-free survival over rituximab alone, regardless of treatment or mutational status.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 7, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Ibrutinib/Rituximab Yields Prolonged PFS in Waldenstr öm Macroglobulinemia
Bryant FurlowJun 4, 2018In the randomized phase III iNNOVATE trial, adding ibrutinib to rituximab significantly improved PFS in patients with Waldenstr öm macroglobulinemia. (Source: CancerNetwork)
Source: CancerNetwork - June 4, 2018 Category: Cancer & Oncology Authors: A Source Type: news

IMBRUVICA ® (ibrutinib) in Combination with Rituximab Showed Greater Efficacy Compared to Placebo Plus Rituximab in Patients with Waldenström’s Macroglobulinemia, a Rare and Incurable Form of Non-Hodgkin’s Lymphoma
(Source: Johnson and Johnson)
Source: Johnson and Johnson - June 2, 2018 Category: Pharmaceuticals Source Type: news

Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016
This research has led to a Practice Changing Update on DynaMed Plus. Itarticle concludes that CHOP plus 131 I tositumomab and CHOP plus rituximab may have similar 5- and 10-year overall survival, but CHOP plus rituximab may improve 10-year progression-free survival in adults with advanced follicular lymphoma. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - May 16, 2018 Category: Consumer Health News Source Type: news

Quiz: Genetics and Epidemiology of Diffuse Large B-Cell Lymphoma
Can you name biomarkers that are associated with PCNS-DLBCL? Are you aware of contraindications for use of rituximab in DLBCL? Test your knowledge by taking this multiquestion quiz. (Source: CancerNetwork)
Source: CancerNetwork - May 15, 2018 Category: Cancer & Oncology Authors: Bryant Furlow Tags: Hematologic Malignancies Quiz Source Type: news

Treatment of Chronic Antibody Mediated Rejection Treatment of Chronic Antibody Mediated Rejection
Is IVIG combined with rituximab a safe and effective treatment option for chronic antibody mediated rejection?American Journal of Transplantation (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 9, 2018 Category: Consumer Health News Tags: Transplantation Journal Article Source Type: news

Roche wins reprieve as Novartis biosimilar delayed in U.S.
LONDON/ZURICH (Reuters) - Roche has won a reprieve an expected deluge of cheaper versions of its biotech cancer drugs as U.S. regulators knocked back a biosimilar form of rituximab from Swiss rival Novartis. (Source: Reuters: Health)
Source: Reuters: Health - May 3, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Novartis biosimilar cancer drug hits U.S. regulatory bump
ZURICH (Reuters) - Novartis AG said its biosimilar version of rituximab to treat blood cancers and immunological diseases such as rheumatoid arthritis had not won regulatory approval from the U.S. Food and Drug Administration (FDA). (Source: Reuters: Health)
Source: Reuters: Health - May 3, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Doses of Rituximab for Retreatment in Rheumatoid Arthritis Doses of Rituximab for Retreatment in Rheumatoid Arthritis
How do standard and reduced dosing of rituximab compare in terms of maintenance and the risk for developing serious infections?Rheumatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 25, 2018 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

Venetoclax/Rituximab Found Superior to Chemotherapy in CLL
The combination of rituximab and the BCL2 inhibitor venetoclax significantly lengthened PFS among CLL patients in the phase III MURANO trial. (Source: CancerNetwork)
Source: CancerNetwork - April 19, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Chronic Lymphocytic Leukemia Hematologic Malignancies News Source Type: news

Treatment for male anti-NMDA receptor encephalitis patients
(Bentham Science Publishers) Treatments for the anti-NMDA receptor encephalitis usually include steroids, intravenous immunoglobulin, plasma exchange, plasmapheresis, rituximab, cyclophosphamide and tumor resection. The researchers aimed to compare the efficacy of the treatments including intravenous immunoglobulin, plasma exchange, plasmapheresis, rituximab or cyclophosphamide for male anti-NMDA receptor encephalitis patients without tumor and to discuss potential biomarkers for this disease. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 14, 2018 Category: Cancer & Oncology Source Type: news